Company was founded to develop a non-invasive, scalable testing solution for COVID-19 using AI machine learning and imaging from smart devices.

April - Proof of Concept - Achieved 93% accuracy detecting diabetic retinopathy

Detected COVID-19 through AI-powered chest X-Rays achieved 89% accuracy

Issued 1st U.S. patent pending certification for:
Deep Neural Network Based Covid-19 Risk Assessment from Retinal Scans Using Smartphone Fundus Photography

Awarded $300K in grants from Fayetteville State University and UNC Pembroke

Issued 2nd U.S. Patent pending certification for:
Deep Neural Network based Covid-19 Risk Assessment from Eye Region Scans

Patent Valued at U.S. $10M from Idea Intellectual | Cert. Patent Valuation Analyst.
.

Received $20M offer from publicly traded company for IP and know how. (declined offer)

Improved accuracy of COVID detection to 90% using only a smartphone.

Teamers signed testing & distribution agreement with COVID Testing LLC in Orlando, FL.

Raised additional $100K at $20M valuation. Funds for validation and FDA EUA/510K

Applied for RADx Grant $2.7M in conjunction with the University of North Carolina at Pembroke.